{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:04:21Z","timestamp":1783663461879,"version":"3.55.0"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Prostate cancer (PCa) incidence and prognosis have changed substantially worldwide in recent decades, driven in part by early detection recommendations. Some countries such as the US have shown a rise in metastatic PCa incidence following recommendations against routine PCa screening around 2012.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate trends in PCa incidence, mortality, and relative survival across age and prognostic groups and guide policy and practice in Switzerland.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study included all registered cases of primary PCa based on data from the Swiss National Agency for Cancer Registration and the Swiss Federal Statistical Office from January 1, 1980, to December 31, 2021. Data were analyzed from January 8, 2024, until February 20, 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Diagnosis of PCa.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Age-standardized incidence and mortality rates and relative survival to 10 years after diagnosis were estimated. Subgroup analyses were conducted by age, Surveillance, Epidemiology, and End Results stage, Union for International Cancer Control stage, and Gleason score.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study included 142\u202f665 cases of primary PCa registered in Switzerland between 1980 and 2021, 100 102 (70.2%) of which were men aged 60 to 79 years. From 1980 to 2004, PCa incidence increased to 226.6 (95% CI, 218.8-234.7) per 100\u202f000 men; it decreased markedly to 173.5 (95% CI, 168.9-178.2) per 100 000 men between 2011 and 2014, then increased again to 220.6 (95% CI, 216.0-225.3) per 100 000 men in 2021. These trends were primarily observed for localized, stage I to II PCa and PCa with a Gleason score of 7 or less in men aged 50 to 79 years. Incidence of distant and stage IV PCa increased after 2011, while incidence of PCa with a Gleason score of 8 to 10 remained relatively stable. PCa mortality declined continuously from the early 1990s to 34.8 (95% CI, 32.9-36.8) per 100\u202f000 men in 2021, while 10-year relative survival increased from 46.2% (95% CI, 43.7%-48.8%) in 1982 to 1991 to 88.5% (95% CI, 86.6%-90.5%) in 2012 to 2021. The 10-year relative survival among men with localized PCa (99.2%; 95% CI, 96.0%-102.4%) was similar compared with men from the general population.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this population-based cohort study, trends in PCa incidence in Switzerland suggest that overdiagnosis of lower-risk PCa increased and that there was a concurrent rise in cancers diagnosed in advanced stages alongside improvements in overall prognosis. These findings further suggest substantial potential for optimizing early detection of PCa.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.8289","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:00:15Z","timestamp":1776783615000},"page":"e268289","source":"Crossref","is-referenced-by-count":2,"title":["Prostate Cancer Incidence, Mortality, and Survival in Switzerland"],"prefix":"10.1001","volume":"9","author":[{"given":"Dominik","family":"Menges","sequence":"first","affiliation":[{"name":"Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland"},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Swiss School of Public Health, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Wildisen","sequence":"additional","affiliation":[{"name":"National Agency for Cancer Registration, Zurich, Switzerland"},{"name":"National Institute for Cancer Epidemiology and Registration, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Scherer","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tancredi","sequence":"additional","affiliation":[{"name":"Swiss School of Public Health, Zurich, Switzerland"},{"name":"Population Health Laboratory, University of Fribourg, Fribourg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"W\u00fcrnschimmel","sequence":"additional","affiliation":[{"name":"University Teaching and Research Hospital, Luzerner Kantonsspital, Lucerne, Switzerland"},{"name":"Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvan","family":"Sigg","sequence":"additional","affiliation":[{"name":"University Teaching and Research Hospital, Luzerner Kantonsspital, Lucerne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Lippuner","sequence":"additional","affiliation":[{"name":"Europa Uomo Switzerland, Ehrendingen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cathomas","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Cantonal Hospital Graub\u00fcnden, Chur, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoud J.","family":"Templeton","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, St Claraspital, Basel, Switzerland"},{"name":"St Clara Research Ltd, Basel, Switzerland"},{"name":"Faculty of Medicine, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Chmiel","sequence":"additional","affiliation":[{"name":"mediX Schweiz, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrill A.","family":"Rentsch","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Basel, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eberli","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Kwiatkowski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Basel, Basel, Switzerland"},{"name":"Department of Urology, Cantonal Hospital Aarau, Aarau, Switzerland"},{"name":"Department of Urology, Academic Hospital Braunschweig, Braunschweig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Mortezavi","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"},{"name":"Department of Urology, University Hospital Basel, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Chiolero","sequence":"additional","affiliation":[{"name":"Swiss School of Public Health, Zurich, Switzerland"},{"name":"Population Health Laboratory, University of Fribourg, Fribourg, Switzerland"},{"name":"School of Population and Global Health, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Rohrmann","sequence":"additional","affiliation":[{"name":"Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland"},{"name":"Cancer Registry Zurich, Zug, Schaffhausen and Schwyz, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Clements","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Staehelin","sequence":"additional","affiliation":[{"name":"National Agency for Cancer Registration, Zurich, Switzerland"},{"name":"National Institute for Cancer Epidemiology and Registration, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"7","key":"zoi260264r1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.1995.03520310046028","article-title":"The role of increasing detection in the rising incidence of prostate cancer.","volume":"273","author":"Potosky","year":"1995","journal-title":"JAMA"},{"issue":"16","key":"zoi260264r2","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMms1914228","article-title":"Reconsidering prostate cancer mortality\u2014the future of PSA screening.","volume":"382","author":"Welch","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi260264r3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10437","key":"zoi260264r4","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases.","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"zoi260264r5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/jpm14010084","article-title":"Health policy for prostate cancer early detection in the European Union and the impact of opportunistic screening: PRAISE-U Consortium.","volume":"14","author":"Beyer","year":"2024","journal-title":"J Pers Med"},{"issue":"5","key":"zoi260264r6","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.57187\/s.3626","article-title":"Prostate cancer screening in Switzerland: a literature review and consensus statement from the Swiss Society of Urology.","volume":"154","author":"W\u00fcrnschimmel","year":"2024","journal-title":"Swiss Med Wkly"},{"key":"zoi260264r7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-077738","article-title":"Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study.","volume":"386","author":"Vaccarella","year":"2024","journal-title":"BMJ"},{"issue":"3","key":"zoi260264r8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update.","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur Urol"},{"issue":"2","key":"zoi260264r9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: US Preventive Services Task Force recommendation statement.","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"issue":"19","key":"zoi260264r10","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1001\/jama.2015.14905","article-title":"Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations.","volume":"314","author":"Jemal","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"zoi260264r11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.6004\/jnccn.2018.7274","article-title":"Prostate-specific antigen testing use and prostate cancer diagnostic stage following the 2012 USPSTF guideline changes.","volume":"17","author":"Magnani","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"5153","key":"zoi260264r12","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20388","article-title":"37-year incidence and mortality time trends of common cancer types by sex, age, and stage in the canton of Zurich.","volume":"150","author":"Wanner","year":"2020","journal-title":"Swiss Med Wkly"},{"issue":"6","key":"zoi260264r13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217879","article-title":"Time trends in prostate cancer screening in Swiss primary care (2010 to 2017)\u2014a retrospective study.","volume":"14","author":"Zechmann","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"zoi260264r15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1001\/jamainternmed.2014.8111","article-title":"Creating a list of low-value health care activities in Swiss primary care.","volume":"175","author":"Selby","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"1","key":"zoi260264r16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/jnci\/djaa068","article-title":"Prostate cancer incidence 5 years after US Preventive Services Task Force recommendations against screening.","volume":"113","author":"Jemal","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"zoi260264r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.2246","article-title":"Trends in incidence of metastatic prostate cancer in the US.","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"zoi260264r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102700","article-title":"Prostate cancer incidence rates, trends, and treatment related to prostate-specific antigen screening recommendations in the United States.","volume":"93","author":"Merrill","year":"2024","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"zoi260264r19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.56825","article-title":"Trends in prostate cancer incidence and mortality rates.","volume":"8","author":"Van Blarigan","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"7-8","key":"zoi260264r20","doi-asserted-by":"publisher","first-page":"E589","DOI":"10.1111\/ans.14275","article-title":"Metastatic prostate cancer incidence in Australia after amendment to prostate-specific antigen screening guidelines.","volume":"88","author":"Smith","year":"2018","journal-title":"ANZ J Surg"},{"issue":"1","key":"zoi260264r21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12894-021-00784-w","article-title":"Impact on prostate cancer clinical presentation after non-screening policies at a tertiary-care medical center\u2014a retrospective study.","volume":"21","author":"Ajami","year":"2021","journal-title":"BMC Urol"},{"issue":"1","key":"zoi260264r22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12894-018-0384-x","article-title":"Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.","volume":"18","author":"Zakaria","year":"2018","journal-title":"BMC Urol"},{"issue":"7","key":"zoi260264r28","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/(SICI)1097-0258(19970415)16:7<791::AID-SIM500>3.0.CO;2-#","article-title":"Confidence intervals for directly standardized rates: a method based on the gamma distribution.","volume":"16","author":"Fay","year":"1997","journal-title":"Stat Med"},{"issue":"7","key":"zoi260264r29","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.csda.2007.11.004","article-title":"Confidence interval estimating procedures for standardized incidence rates.","volume":"52","author":"Ng","year":"2008","journal-title":"Comput Stat Data Anal"},{"issue":"15","key":"zoi260264r32","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.ejca.2004.07.002","article-title":"Standard cancer patient population for age standardising survival ratios.","volume":"40","author":"Corazziari","year":"2004","journal-title":"Eur J Cancer"},{"key":"zoi260264r33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12874-015-0057-3","article-title":"Comparison of different approaches to estimating age standardized net survival.","volume":"15","author":"Lambert","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"zoi260264r35","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamaoncol.2024.0734","article-title":"Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis.","volume":"10","author":"Fazekas","year":"2024","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi260264r36","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41391-024-00852-w","article-title":"Risk calculators for the detection of prostate cancer: a systematic review.","volume":"27","author":"Denijs","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"15","key":"zoi260264r39","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/jama.2009.1498","article-title":"Rethinking screening for breast cancer and prostate cancer.","volume":"302","author":"Esserman","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"zoi260264r40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates.","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"zoi260264r41","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/jnci\/djae200","article-title":"When is prostate cancer really cancer?","volume":"117","author":"Cooperberg","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi260264r42","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1186\/s12889-025-22848-4","article-title":"Cancer screening outside of age recommendations: a population-based study.","volume":"25","author":"Smit","year":"2025","journal-title":"BMC Public Health"},{"key":"zoi260264r43","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071082","article-title":"Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit.","volume":"381","author":"Vickers","year":"2023","journal-title":"BMJ"},{"issue":"17","key":"zoi260264r44","doi-asserted-by":"crossref","first-page":"18165","DOI":"10.1002\/cam4.6392","article-title":"Time-trends and age and stage differences in 5-year relative survival for common cancer types by sex in the canton of Zurich, Switzerland.","volume":"12","author":"Wanner","year":"2023","journal-title":"Cancer Med"},{"key":"zoi260264r45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ypmed.2015.11.009","article-title":"Prostate cancer screening in Switzerland: 20-year trends and socioeconomic disparities.","volume":"82","author":"Guessous","year":"2016","journal-title":"Prev Med"},{"issue":"4","key":"zoi260264r46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231409","article-title":"Variation of colorectal, breast and prostate cancer screening activity in Switzerland: influence of insurance, policy and guidelines.","volume":"15","author":"Ulyte","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"zoi260264r47","first-page":"126","article-title":"PSA determination\u2014recommendation of the Swiss Society of Urology (SGU).","volume":"12","author":"Gasser","year":"2012","journal-title":"Swiss Medical Forum"},{"issue":"10","key":"zoi260264r49","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/aje\/kwab146","article-title":"Comparison of relative survival and cause-specific survival in men with prostate cancer according to age and risk category: a nationwide, population-based study.","volume":"190","author":"Orrason","year":"2021","journal-title":"Am J Epidemiol"},{"issue":"3","key":"zoi260264r50","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.21037\/tau-20-853","article-title":"Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?","volume":"10","author":"Montironi","year":"2021","journal-title":"Transl Androl Urol"},{"key":"zoi260264r30","volume-title":"Instructions to IBM 650 Programmers in Processing Survival Computations","author":"Ederer","year":"1959"},{"key":"zoi260264r14","unstructured":"The significance of PSA levels in the early detection of prostate cancer (2011). Swiss Medical Board. 2011. Accessed February 23, 2026. https:\/\/www.swissmedicalboard.ch\/index.php?id=70&no_cache=1&tx_news_pi1%5Bnews%5D=43&cHash=56d07d12184cc7549fb000939fd90f94"},{"key":"zoi260264r23","unstructured":"Swiss national cancer dataset. National Agency for Cancer Registration. 2025. Accessed February 23, 2026. https:\/\/nacr.ch\/en\/information-for-researchers"},{"key":"zoi260264r24","unstructured":"History of cancer registration in Switzerland. National Agency for Cancer Registration. 2026. Accessed February 23, 2026. https:\/\/nacr.ch\/en\/history-of-cancer-registration-in-switzerland"},{"key":"zoi260264r25","unstructured":"Swiss cause of death and stillbirth statistics. Swiss Federal Statistical Office (SFSO). 2026. Accessed February 23, 2026. https:\/\/www.bfs.admin.ch\/bfs\/en\/home\/statistics\/health\/surveys\/ecod.html"},{"key":"zoi260264r26","unstructured":"Abawi? K, Feller? A, Lorez? M, . Statistical methods for cancer reporting in Switzerland (version 1.0). 2022. Accessed February 23, 2026. https:\/\/nacr.ch\/upload\/downloads\/Berichte%20und%20Statistiken\/Methodenbericht\/Methodology_report_v1_en.pdf"},{"key":"zoi260264r27","unstructured":"Revision of the European standard population. Publications Office of the European Union. 2013. Accessed February 23, 2026. https:\/\/op.europa.eu\/publication-detail\/-\/publication\/69399636-1113-4a38-9ad1-269c33d0dc01"},{"key":"zoi260264r31","unstructured":"Period life tables for Switzerland (1876-2150) by year, sex and age. Swiss Federal Statistical Office. 2023. Accessed February 23, 2026. https:\/\/www.bfs.admin.ch\/asset\/de\/30025875"},{"key":"zoi260264r34","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. 2017. Accessed February 23, 2026. https:\/\/www.R-project.org\/"},{"key":"zoi260264r37","unstructured":"Last prostate examination. Swiss Federal Statistical Office. 2024. Accessed February 23, 2026. https:\/\/www.bfs.admin.ch\/asset\/de\/30305992"},{"key":"zoi260264r38","unstructured":"Swiss Health Care Atlas: prostate specific antigen (PSA) test. Swiss Federal Statistical Office. 2024. Accessed February 23, 2026. https:\/\/www.versorgungsatlas.ch\/en\/indicator\/_088\/a"},{"key":"zoi260264r48","unstructured":"Swiss annual Data Quality Report (aDQR) 2022\u2014executive summary. National Agency for Cancer Registration (NACR). September 29, 2023. Accessed February 23, 2026. https:\/\/nacr.ch\/upload\/downloads\/Berichte%20und%20Statistiken\/Datenqualit%C3%A4t\/FINAL_Executive_summary_29-Sept-2023_EN.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847991\/menges_2026_oi_260264_1776190660.83864.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:00:23Z","timestamp":1776783623000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.8289","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}